` ONCY (Oncolytics Biotech Inc) vs S&P 500 Comparison - Alpha Spread

ONCY
vs
S&P 500

Over the past 12 months, ONCY has underperformed S&P 500, delivering a return of +12% compared to the S&P 500's +14% growth.

Stocks Performance
ONCY vs S&P 500

Loading
ONCY
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ONCY vs S&P 500

Performance Gap Between ONCY and GSPC
HIDDEN
Show

Performance By Year
ONCY vs S&P 500

Loading
ONCY
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Oncolytics Biotech Inc vs Peers

S&P 500
ONCY
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Oncolytics Biotech Inc
Glance View

Market Cap
76.2m USD
Industry
Biotechnology

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

ONCY Intrinsic Value
Not Available
Back to Top